Table 2.

Reasons for discontinuation of ibrutinib treatment in 747 patients.

	N. of patients	%
Discontinued	397	100%
Progression or death	182	45.8
Discontinued except progression	215	54.2
Toxicity	37	9.3
Medical or patient decision	33	8.3
Lost to follow-up	108	27.3
Others (no drug related)	37	9.3